Skip to content
Axcess News – Lifestyle
Author:
Alector, Inc.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
April 29, 2026
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 6, 2026
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
March 5, 2026